Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
Evolus’ Jeuveau (DWP-450) (prabotulinumtoxinA) will likely prove to be a strong competitor to Allergan’s Botox (botulinum toxin type...
Sumitomo Dainippon announces good results from trial of its lead drug
Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into...
Vaxelis approval boosts Merck and Sanofi’s foothold in US childhood vaccines
In late December, Merck and Sanofi secured FDA approval for Vaxelis (diphtheria, tetanus, and acellular...
US lawmakers to introduce new bills to slash prescription drug prices
US Senator Bernie Sanders and Representative Elijah Cummings have announced plans to introduce three new...
NICE declines to endorse Novartis’ pricey migraine drug Aimovig
National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine...
Can BMS make a success of its Celgene acquisition?
Pharmaceutical company Bristol-Myers Squibb has bought US biotech Celgene for $74bn as it seeks to...
CANbridge Pharmaceuticals expands partnership with Wuxi Biologics
China’s CANbridge Pharmaceuticals has expanded its alliance with WuXi Biologics for the discovery, development and...
Smart speaker solution to patient care debuted at CES 2019
With an ageing population, more people than ever are relying on carers, be it professionals...
Tough enrolment criteria for Phase IIa trial of Allakos’s chronic urticaria drug
Allakos’s Phase IIa AK002 trial in chronic spontaneous urticaria had challenging enrolment criteria, two investigators...
AAPS 2018: entering a new era of ultra-pure synthetic cannabinoids
As the US increases the state-approved production and supply of cannabis-derived pharmaceutical products, there are...